CHNXF / ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that it made significant progress in deleveraging its balance sheet and improving its working cap more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors it has received a notice of allowance for a key patent in the US and Canada. The company noted th more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has concluded the enrolment of 20 subjects in its US multi-site rotator cuff tear repair Phase I/II clin more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has noted that patient recruitment for its rotator cuff repair Phase I/II trial reached an important milestone� more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has partnered with Bruder Consulting & Venture Group (BCVG) as its exclusive advisory firm for the pur more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has closed its amended non-brokered private placement offering for gross proceeds of $3.86 million. The more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a non-brokered private placement offering of 12,500,000 units at a price of $0.20 each for gross p more_horizontal

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has obtained, in partnership with Polytechnique Montréal, a $3,472,000 grant from The Natural Sciences more_horizontal